• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Prevalence of erectile dysfunction as long-COVID symptom in hospitalized Japanese patients

tetano

Editor, Senior Moderator
Sci Rep


. 2025 Feb 21;15(1):6279.
doi: 10.1038/s41598-025-88904-6. Prevalence of erectile dysfunction as long-COVID symptom in hospitalized Japanese patients

Hideaki Kato[SUP] 1 [/SUP], Nao Ichihara[SUP] 2 3 [/SUP], Hiroki Saito[SUP] 4 5 [/SUP], Shigeki Fujitani[SUP] 4 [/SUP], Kohei Ota[SUP] 6 [/SUP], Yuji Takahashi[SUP] 7 [/SUP], Toshiyuki Harada[SUP] 8 [/SUP], Takeshi Hattori[SUP] 9 [/SUP], Mitsuru Komeya[SUP] 10 [/SUP], Mariko Hosozawa[SUP] 11 [/SUP], Yoko Muto[SUP] 11 [/SUP], Miyuki Hori[SUP] 11 [/SUP], Arisa Iba[SUP] 11 [/SUP], Hiroyasu Iso[SUP] 11 [/SUP], Hiroyasu Iso[SUP] 11 [/SUP]; COVID-19 Recovery Study II Group



Collaborators, Affiliations
Abstract

Coronavirus disease-2019 (COVID-19) is associated with a wide range of post-acute sequelae. The prevalence of erectile dysfunction (ED) that developed after COVID-19 and the associated underlying factors were analyzed based on a questionnaire survey, COVID-19 Recovery Study II in Japan. A case-control study was conducted with those with or without ED one and two years hospitalized with COVID-19 between March and September 2021. Six hundred and nine Japanese men, with a median age of 48 years, were analyzed. During the study period, 116 subjects (19.0%) had erectile dysfunction. The patients with ED responded with less subjective awareness of recovery and high breathless and fatigue scores compared to those without ED. The patients with ED also showed higher Hospital Anxiety and Depression Scale-D (depression) and the EuroQol 5-dimensions 5-level scores for pain/discomfort and anxiety/depression scores compared before COVID-19 infection. Sleep disturbance was suggested to be associated with erectile dysfunction using an exploratory clustering analysis in the one-year survey. There were no associations of COVID-19 severity, reinfection, vaccination frequency, antiviral treatment for COVID-19 with the presence of erectile dysfunction. It was considered that mental support for the subject with erectile dysfunction as a long-COVID symptom is warranted.

Keywords: COVID-19 Recovery Study II (CORES II); Coronavirus disease-2019 (COVID-19); Erectile dysfunction; Post-acute sequelae; Sleep disorder.

 
Back
Top Bottom